We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL).
- Authors
Melani, C. J.; Lakhotia, R.; Pittaluga, S.; Phelan, J. D.; Yang, Y.; Davies‐Hill, T.; Simard, J.; Muppidi, J.; Huang, D. W.; Thomas, C. J.; Ceribelli, M.; Tosto, F. A.; Pradhan, A.; Juanitez, A. M.; Rimsza, L. M.; Jacob, A.; Simmons, H.; Steinberg, S. M.; Jaffe, E. S.; Staudt, L. M.
- Abstract
B Methods: b R/R and TN MCL pts with adequate organ function were eligible. B Introduction: b MCL is incurable with standard chemotherapy. Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment-naïve (TN) mantle cell lymphoma (MCL).
- Subjects
MANTLE cell lymphoma; LENALIDOMIDE; VENETOCLAX; REFRACTORY materials; PREDNISONE
- Publication
Hematological Oncology, 2023, Vol 41, p582
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_437